JP Patent

JP2019108395A — Ｂｔｋ阻害剤としての４−イミダゾピリダジン−１−イル−ベンズアミドおよび４−イミダゾトリアジン−１−イル−ベンズアミド

Assigned to Organon Pharma UK Ltd · Expires 2019-07-04 · 7y expired

What this patent protects

【課題】ブルトン型チロシンキナーゼ（Ｂｔｋ）媒介障害の処置に有効な化合物の提供。【解決手段】下記式を代表例とする６〜５員縮合ピリジン環化合物。【選択図】なし

USPTO Abstract

【課題】ブルトン型チロシンキナーゼ（Ｂｔｋ）媒介障害の処置に有効な化合物の提供。【解決手段】下記式を代表例とする６〜５員縮合ピリジン環化合物。【選択図】なし

Drugs covered by this patent

Patent Metadata

Patent number
JP2019108395A
Jurisdiction
JP
Classification
—
Expires
2019-07-04
Drug substance claim
No
Drug product claim
No
Assignee
Organon Pharma UK Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.